Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats

B Vitamins and Fatty Acids: What Do They Share with Small Vessel Disease-Related Dementia?

Many studies have been written on vitamin supplementation, fatty acid, and dementia, but results are still under debate, and no definite conclusion has yet been drawn. Nevertheless, a significant amount of lab evidence confirms that vitamins of the B group are tightly related to gene control for endothelium protection, act as antioxidants, play a co-enzymatic role in the most critical biochemical reactions inside the brain, and cooperate with many other elements, such as choline, for the synthesis of polyunsaturated phosphatidylcholine, through S-adenosyl-methionine (SAM) methyl donation. B-vitamins have anti-inflammatory properties and act in protective roles against neurodegenerative mechanisms, for example, through modulation of the glutamate currents and a reduction of the calcium currents. In addition, they also have extraordinary antioxidant properties. However, laboratory data are far from clinical practice. Many studies have tried to apply these results in everyday clinical activity, but results have been discouraging and far from a possible resolution of the associated mysteries, like those represented by Alzheimer's disease (AD) or small vessel disease dementia. Above all, two significant problems emerge from the research: No consensus exists on general diagnostic criteria-MCI or AD? Which diagnostic criteria should be applied for small vessel disease-related dementia? In addition, no general schema exists for determining a possible correct time of implementation to have effective results. Here we present an up-to-date review of the literature on such topics, shedding some light on the possible interaction of vitamins and phosphatidylcholine, and their role in brain metabolism and catabolism. Further studies should take into account all of these questions, with well-designed and world-homogeneous trials.

Effect of dietary niacin supplementation on performance, total tract nutrient retention, carcass yield and meat lipid profile of growing turkeys

A study was conducted to investigate the influence of dietary high or recommended nicotinic acid (niacin) supplementation on growth performance, total tract nutrient digestibility, hematology, serum chemistry, and lipoprotein concentrations in the serum and meat of growing turkeys. Turkeys were assigned to three treatments on weight equalisation basis with five replicates of eight turkeys in each group. Experimental diets were: no supplemental niacin (Control), a diet supplemented with 60 mg/kg niacin termed as recommended niacin supplementation and a diet supplemented with 180 mg/kg niacin termed as high niacin supplementation (HNS). The experiment lasted for the grower (Day 56–84) and finisher phases (Day 84–112) of the birds. Dietary inclusion of HNS increased (P < 0.01) bodyweight gain, metabolisable energy (Days 84 and 112), dressing percentage and retail cut parts of turkeys (Day 112) in relation to the Control-fed turkeys. Furthermore, least white blood cell count and higher concentrations of packed cell volume, red blood cells and hemoglobin (P < 0.01) were found in turkeys fed HNS on Days 84 and 112. Similarly, turkeys in the HNS group had improved serum constituents including serum protein, uric acid, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphate. The blood and meat lipid profile analysis showed that low density lipoprotein and total cholesterol were least (P < 0.05) in turkeys fed HNS. Collectively, dietary high supplementation of niacin (180 mg/kg) improves production performances, reduces serum and meat fat content and improve indicators of stress resistance ability in growing turkeys.

Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients

Background

The aim of this study was to explore the influence of extended-release niacin/laropiprant (ERN/LRP) versus placebo on high-density lipoprotein (HDL) antioxidant function, cholesterol efflux, apolipoprotein B100 (apoB)-containing lipoproteins, and mediators of vascular inflammation associated with 15% increase in high-density lipoprotein cholesterol (HDL-C). Study patients had persistent dyslipidemia despite receiving high-dose statin treatment.

Methods and Results

In a randomized double-blind, placebo-controlled, crossover trial, we compared the effect of ERN/LRP with placebo in 27 statin-treated dyslipidemic patients who had not achieved National Cholesterol Education Program-ATP III targets for low-density lipoprotein cholesterol (LDL-C). We measured fasting lipid profile, apolipoproteins, cholesteryl ester transfer protein (CETP) activity, paraoxonase 1 (PON1) activity, small dense LDL apoB (sdLDL-apoB), oxidized LDL (oxLDL), glycated apoB (glyc-apoB), lipoprotein phospholipase A2 (Lp-PLA2), lysophosphatidyl choline (lyso-PC), macrophage chemoattractant protein (MCP1), serum amyloid A (SAA) and myeloperoxidase (MPO). We also examined the capacity of HDL to protect LDL from in vitro oxidation and the percentage cholesterol efflux mediated by apoB depleted serum. ERN/LRP was associated with an 18% increase in HDL-C levels compared to placebo (1.55 versus 1.31 mmol/L, P<0.0001). There were significant reductions in total cholesterol, triglycerides, LDL cholesterol, total serum apoB, lipoprotein (a), CETP activity, oxLDL, Lp-PLA2, lyso-PC, MCP1, and SAA, but no significant changes in glyc-apoB or sdLDL-apoB concentration. There was a modest increase in cholesterol efflux function of HDL (19.5%, P=0.045), but no change in the antioxidant capacity of HDL in vitro or PON1 activity.

Conclusions

ERN/LRP reduces LDL-associated mediators of vascular inflammation, but has varied effects on HDL functionality and LDL quality, which may counter its HDL-C-raising effect.

Clinical Trial Registration

URL: http://www.clinicaltrials.gov. Unique identifier: NCT01054508.

Impact of chromium histidinate on high fat diet induced obesity in rats

Background

Chromium (Cr) is an essential trace element that has garnered interest for use as a weight loss aid, but its molecular mechanism in obesity is not clear. In this study, an attempt has been made to investigate the effects of chromium histidinate (CrHis) on glucose transporter-2 (GLUT-2), nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), nuclear factor-kappa B (NF-κB p65) and the oxidative stress marker 4-hydroxynonenal adducts (HNE) expressions in liver of rats fed high fat diet (HFD).

Methods

Male Wistar rats (n = 40, 8 wk-old) were divided into four groups. Group I was fed a standard diet (12% of calories as fat); Group II was fed a standard diet and supplemented with 110 μg CrHis/kg BW/d; Group III was fed a HFD (40% of calories as fat); Group IV was fed HFD and supplemented with 110 μg CrHis/kg BW/d.

Results

Rats fed HFD possessed greater serum insulin (40 vs.33 pmol/L) and glucose (158 vs. 143 mg/dL) concentration and less liver Cr (44 vs.82 μg/g) concentration than rats fed the control diet. However, rats supplemented with CrHis had greater liver Cr and serum insulin and lower glucose concentration in rats fed HFD (P < 0.05). The hepatic nuclear factor-kappa B (NF-κB p65) and HNE were increased in high fat group compared to control group, but reduced by the CrHis administration (P < 0.05). The levels of hepatic Nrf2 and HO-1 were increased by supplementation of CrHis (P < 0.05).

Conclusion

These findings demonstrate that supplementation of CrHis is protective against obesity, at least in part, through Nrf2-mediated induction of HO-1 in rats fed high fat diet.

The hypocholesterolemic and antioxidative effect of dietary diosgenin and chromium chloride supplementation on high-cholesterol fed Japanese quails

The current study investigated the effect of natural diosgenin extracted from fenugreek seeds, in comparison with the pure standard diosgenin, plus chromium chloride (CrCl3) supplementation on high-cholesterol fed Japanese quails. Quails were randomly divided into four groups. Group one (n = 25) fed experimental diet only (control; contained basal diet supplemented with 1% cholesterol), group 2 (n = 20) fed experimental diet supplemented with CrCl3 only (400 microg kg(-1) of body weight), groups 3 and 4 (n = 30 per group) were fed experimental diet supplemented with either 0.5% (w/w) of extracted diosgenin plus CrCl3 or pure standard diosgenin (0.5%) plus CrCl3 respectively, for 12 days. Blood samples were collected at days 0 and 12 for measuring levels of lipid profile. The work was carried out at Applied Science University and Amman University, Amman, Jordan during the period from October 2009 through October 2010. The mean levels of total cholesterol (TC) in control quails at d12 was significantly (p < 0.01) increased compare to those at d0. Supplementation of diet with CrCl3 alone or CrCl3 with diosgenin either extracted or pure standard for 12 days showed a significant (p < 0.01) decrease in TC and low density lipoprotein cholesterol (LDL-C) levels as compared to those in the control quails. While, high density lipoprotein cholesterol (HDL-C) increased significantly (p < 0.01) in quails supplemented with diosgenin and CrCl3. At d12, the mean Superoxide Dismutase (SOD) activities in erythrocytes of quails in all supplemented groups was significantly (p < 0.01) increased as compared to those in control group and was more pronounced in erythrocytes of quails supplemented with pure standard diosgenin plus CrCl3. These results indicated that the combined diosgenin and CrCl3 supplementation to high-cholesterol fed quails might induce a protective effect by both regulating lipid and antioxidative damage.